Skip to main content

Table 1 Main trial testing temozolomide in neuro-endocrine carcinomas (ORR;PFS;OS)

From: Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma

References

Regimens

ORR (%)

PFS (ms)

OS (ms)

Moertel [11]

Etoposide130 mg/mq iv ds 1–3 plus Cisplatin 45 mg/m2 iv ds 2–3

67

8

19

Ekeblad [14]

Temozolomide 200 mg/m2 os ds 1–5, q28

14

7

16

Welin [18]

Temozolomide 150–200 mg/m2 os ds 1–5, q28 ± Capecitabine 1000 mg os bid or 750 mg bid, ds 1–14

33

6

22

Strosberg [17]

Capecitabine 750 mg/m2 os bid, ds 1–14 plus Temozolomide 200 mg/m2 os ds 10–14, q28

70

18

n.d.